JNJ

186.16

-1.49%↓

ABT

123.72

+0.11%↑

TMO

565.18

-0.5%↓

ISRG

544.08

+1.81%↑

DHR

214.08

-0.71%↓

JNJ

186.16

-1.49%↓

ABT

123.72

+0.11%↑

TMO

565.18

-0.5%↓

ISRG

544.08

+1.81%↑

DHR

214.08

-0.71%↓

JNJ

186.16

-1.49%↓

ABT

123.72

+0.11%↑

TMO

565.18

-0.5%↓

ISRG

544.08

+1.81%↑

DHR

214.08

-0.71%↓

JNJ

186.16

-1.49%↓

ABT

123.72

+0.11%↑

TMO

565.18

-0.5%↓

ISRG

544.08

+1.81%↑

DHR

214.08

-0.71%↓

JNJ

186.16

-1.49%↓

ABT

123.72

+0.11%↑

TMO

565.18

-0.5%↓

ISRG

544.08

+1.81%↑

DHR

214.08

-0.71%↓

Kodu・Aktsiate loetelu・Baxter International Inc

Baxter International Inc

Suletud

SektorTervishoid

18.2 -1.41

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

18.04

Max

18.46

Põhinäitajad
By Trading Economics
Sissetulek	58M 122M
Müük	185M 2.8B
P/E Sektori keskmine	86.308 37.003
Dividenditootlus	3.48
Kasumimarginaal	4.342
Töötajad	38,000
EBITDA	137M 462M

Soovitused
By TipRanks
Soovitused	Neutraalne
12 kuu keskmine prognoos	+28.15% upside

Dividendid
By Dow Jones
Dividenditootlus Sektori keskmine	3.48% 2.25%
Järgmine aktsia dividendi kuupäev (ex-date)	28. nov 2025

Turustatistika
By TradingEconomics
Turukapital	-2.7B 12B
Eelmine avamishind	19.61
Eelmine sulgemishind	18.2

Uudiste sentiment

By Acuity

82%

18%

347 / 373 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Weak Bullish Evidence

30.475 / 31.345 Toetus ja vastupanu

Baxter International Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

2. nov 2025, 22:13 UTC

Tulu

Westpac Raises Dividend Despite 1% Slip in Annual Profit -- Update

2. nov 2025, 21:23 UTC

Tulu

Westpac Raises Dividend Despite 1% Slip in Annual Profit

2. nov 2025, 23:43 UTC

Market Talk

Gold Falls on Reports of China's Finance Ministry Ending Tax Incentive for Gold Sales -- Market Talk

2. nov 2025, 23:34 UTC

Market Talk

Oil Rises as OPEC+ Signals Output-Increase Pause -- Market Talk

2. nov 2025, 21:00 UTC

Tulu

Westpac Has Set Tech Overhaul Goals and Will Share Progress, CEO Says>WBC.AU

2. nov 2025, 21:00 UTC

Tulu

Westpac Is Now Executing on Tech Overhaul, CEO Says>WBC.AU

2. nov 2025, 21:00 UTC

Tulu

Westpac Has Completed Tech Overhaul's Discovery and Planning Phases, CEO Says >WBC.AU

2. nov 2025, 20:55 UTC

Tulu

Westpac FY Australia Mortgage Lending Up 5% on Year>WBC.AU

2. nov 2025, 20:55 UTC

Tulu

Westpac FY Institutional Lending Up 17% on Year>WBC.AU

2. nov 2025, 20:55 UTC

Tulu

Westpac FY Business Lending Up 15% on Year>WBC.AU

2. nov 2025, 20:46 UTC

Tulu

Westpac Expects Completion in 2H of FY 2026>WBC.AU

2. nov 2025, 20:46 UTC

Tulu

Westpac Expects CET1 Capital Ratio to Rise by 20 Basis Points>WBC.AU

2. nov 2025, 20:45 UTC

Tulu

Westpac: Sale Is at Slight Premium to Expected Gross Loan Value at Completion>WBC.AU

2. nov 2025, 20:44 UTC

Tulu

Westpac Selling to Consortium Including KKR, Pimco and Pepper Money>WBC.AU

2. nov 2025, 20:43 UTC

Tulu

Westpac Agrees to Sell A$21.4B Rams Mortgage Portfolio>WBC.AU

2. nov 2025, 20:42 UTC

Tulu

Westpac FY Impairment Provisions A$4.99B Vs. A$5.10B>WBC.AU

2. nov 2025, 20:41 UTC

Tulu

Westpac FY Net Profit Ex-Notable Items A$7.0B, Down 2% on Year>WBC.AU

2. nov 2025, 20:40 UTC

Tulu

Westpac FY Customer Deposits A$723.0B Vs. A$673.6B>WBC.AU

2. nov 2025, 20:39 UTC

Tulu

Westpac FY Total Loans A$851.85B Vs. A$806.77B>WBC.AU

2. nov 2025, 20:37 UTC

Tulu

Westpac FY24 Impairment Charges 5 Bps of Loans Vs. 7 Bps in FY25>WBC.AU

2. nov 2025, 20:37 UTC

Tulu

Westpac FY Operating Expenses A$11.92B Vs. A$10.94B>WBC.AU

2. nov 2025, 20:37 UTC

Tulu

Westpac FY Non-Interest Income A$3.00B Vs. A$2.835B>WBC.AU

2. nov 2025, 20:36 UTC

Tulu

Westpac FY Net Interest Income A$19.38B Vs. A$18.75B>WBC.AU

2. nov 2025, 20:35 UTC

Tulu

Westpac FY CET1 Level 2 Capital Ratio 12.5% Vs. 12.5%>WBC.AU

2. nov 2025, 20:35 UTC

Tulu

Westpac FY Net Interest Margin 1.94% Vs. 1.95%>WBC.AU

2. nov 2025, 20:35 UTC

Tulu

Westpac Raises Dividend to A$0.77 Vs. A$0.76 >WBC.AU

2. nov 2025, 20:34 UTC

Tulu

Westpac FY Rev A$22.38B Vs. A$21.59B >WBC.AU

2. nov 2025, 20:33 UTC

Tulu

Westpac FY Net A$6.92B Vs. Net A$6.99B >WBC.AU

2. nov 2025, 14:27 UTC

Tulu

Berkshire Operating Profits Rose 33% in Third Quarter. There Were No Stock Buybacks. -- Barrons.com

2. nov 2025, 14:25 UTC

Tulu

Warren Buffett Is Leaving Berkshire Hathaway in Great Shape for His Successor After Profit Results -- Barrons.com

Võrdlus sarnastega

Hinnamuutus

Baxter International Inc Prognoos

Hinnasiht

By TipRanks

28.15% tõus

12 kuu keskmine prognoos

Keskmine 23.67 USD 28.15%

Kõrge 36 USD

Madal 19 USD

Põhineb 10 Wall Streeti analüütiku instrumendi Baxter International Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Neutraalne

10 ratings

Osta

Hoia

Müü

Põhineb 10 analüütiku instrumendi Baxter International Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

30.475 / 31.345Toetus ja vastupanu

Recent bullish events outweigh bearish events.

Recent bearish events outweigh bullish events.

All events are bearish.

Sentiment

By Acuity

347 / 373 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Baxter International Inc

Baxter International Inc., through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company operates through four segments: Medical Products and Therapies, Healthcare Systems and Technologies, Pharmaceuticals, and Kidney Care. The company offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; generic injectable pharmaceuticals; surgical hemostat and sealant products, advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space, including surgical video technologies, precision positioning devices, and other accessories. It also provides administrative sets; adhesion prevention products; inhaled anesthesia; drug compounding; chronic and acute dialysis therapies and services, including peritoneal dialysis (PD), hemodialysis (HD), continuous renal replacement therapies (CRRT), and other organ support therapies. The company's products are used in hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, ambulatory surgery centers, doctors' offices, and patients at home under physician supervision. The company sells its products through direct sales force, as well as through independent distributors, drug wholesalers, and specialty pharmacy or other alternate site providers in approximately 100 countries. It has an agreement with Celerity Pharmaceutical, LLC to develop acute care generic injectable premix and oncolytic products; and a collaborative research agreement with Miromatrix Medical Inc. aiming to advance care for patients with acute liver failure. Baxter International Inc. was incorporated in 1931 and is headquartered in Deerfield, Illinois.